Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malaria preventive therapy in children with sickle cell anemia in East Africa
PACTR201707002371165Recruiting
- Sponsor
- Duke Clinical Research Institute
- Start
- Oct 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of proguanil, sulfadoxine + pyrimethamine + amodiaquine and dihydroartemisinin + piperaquine in malaria (3 arms), sponsored by Duke Clinical Research Institute. Primary endpoint: RDT-positive P falciparum malaria. Started Oct 2017; status: recruiting.
02
Drugs
proguanilsulfadoxine + pyrimethamine + amodiaquinedihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201707002371165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201707002371165.